The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma
Authors:
- Andreas M. StarkASAndreas M. Stark
- Alexander DoukasADAlexander Doukas
- Heinz-Hermann HugoHHHeinz-Hermann Hugo
- H. Maximilian MehdornHMH. Maximilian Mehdorn
- 1 October 2010
- journal article
- Published by Taylor & Francis in Neurological Research
- Vol. 32 (8) , 816-820
Abstract
There is a growing body of evidence that deficiency of DNA mismatch repair proteins other than O(6)-methylguanine-DNA methyltransferase (MGMT) also contributes to glioblastoma recurrence. We examined the protein expression of MLH1, MSH2 and MSH6 in paired initial and recurrent glioblastoma and compared the results to the Ki67 proliferation index and patient survival. Forty-two patients were included who met the following inclusion criteria: (1) histologically confirmed primary glioblastoma; (2) total tumour resection at initial craniotomy; (3) re-craniotomy for recurrence. Immunohistochemical staining was performed using specific monoclonal antibodies against MLH1, MSH2, MSH6 and Ki67. Chi-square test, Wilcoxon test and log-rank test (Cox-Mantel) were used for statistical analysis. In recurrent tumours, MLH1 expression was significantly reduced. MLH1, MSH2 and MSH6 expression in initial lesions was significantly associated with the Ki67 proliferation index. MLH1 and MSH2 expression in recurrent lesions was also significantly associated with the Ki67 proliferation index. MLH1 and MSH6 positivities in initial lesions were indicators of reduced patient survival. Our results indicate a potential important role of MLH1 and MSH6 in glioblastoma progression. Specific attention should be given on the role of MLH1 and MSH6 in patients with glioblastoma recurrence during temozolomide treatment.Keywords
This publication has 17 references indexed in Scilit:
- Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancerAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2008
- Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant GliomaClinical Cancer Research, 2008
- Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastomaNeuro-Oncology, 2008
- DNA MISMATCH REPAIRAnnual Review of Biochemistry, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Glioblastoma multiforme—report of 267 cases treated at a single institutionSurgical Neurology, 2005
- Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomasJournal of Neurosurgery, 2004
- Molecular Mechanisms Associated with Chromosomal and Microsatellite Instability in Sporadic Glioblastoma multiformeOncology, 2004
- Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrenceCancer, 2002
- Primary and secondary glioblastomas: From concept to clinical diagnosisNeuro-Oncology, 1999